Clinical Trials
2 trialsNCT00385827 2014-08-20
A Safety and Efficacy Study of Siltuximab (CNTO 328) in Male Subjects With Metastatic Hormone-Refractory Prostate Cancer (HRPC)
Centocor, Inc.
Phase 2 Terminated
NCT01309412 2014-05-19
A Phase 1 Study of CNTO 328 (Siltuximab) in Relapsed or Refractory Multiple Myeloma
Janssen Pharmaceutical K.K.
Phase 1 Terminated